In DATA-Switch , women originally assigned to teriparatide received denosumab ( teriparatide to denosumab group ) , those originally assigned to denosumab received teriparatide ( denosumab to teriparatide group ) , and those originally assigned to both received an additional 24 months of denosumab alone ( combination to denosumab group ) .